XML 54 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholders' Equity (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The grant date fair value of the Company’s stock options granted (excluding the stock options granted to the CEO outlined above) was estimated using the following weighted average assumptions:

Year Ended December 31,
202320222021
Expected term (in years)6.026.025.94
Expected volatility49.9 %48.0 %58.6 %
Risk-free interest rate4.2 %2.0 %0.9 %
Expected dividend yield— %— %— %
Share-based Payment Arrangement, Option, Activity
Option activity (excluding the stock options granted to the CEO outlined above) is as follows (in thousands, except for weighted average exercise price and weighted average contractual term in years):
 
SharesWeighted
Average
Exercise
Price		Weighted
Average
Contractual
Period
(in Years)		Aggregate
Intrinsic
Value
Outstanding at December 31, 202214,450 $4.68 7.98$35,771 
Granted603 11.53 
Exercised(912)1.74 
Forfeited and expired(357)6.50 
Outstanding at December 31, 202313,784 5.14 7.1457,972 
Exercisable as of December 31, 20239,688 4.55 6.6845,759 
Share-based Payment Arrangement, Option, Exercise Price Range
The options outstanding and exercisable as of December 31, 2023 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price):

Options OutstandingOptions Exercisable
Exercise PriceSharesWeighted
Average
Remaining
Contractual
Life (in
Years)		SharesWeighted
Average
Remaining
Contractual
Life (in
Years)
$0.06 – 0.40
1,422 4.231,422 4.23
1.55 – 1.75
760 5.37760 5.37
2.43 – 3.11
2,751 6.432,751 6.43
5.01 – 6.82
5,913 8.182,690 8.18
8.13 – 11.53
2,127 7.681,499 7.20
12.21 – 15.17
811 7.32566 7.31
13,784 9,688 
The options outstanding and exercisable as of December 31, 2022 (excluding the stock options granted to the CEO outlined above) have been aggregated into ranges for additional disclosure as follows (in thousands, except weighted average remaining contractual life and exercise price):

Options OutstandingOptions Exercisable
Exercise PriceSharesWeighted
Average
Remaining
Contractual
Life (in
Years)		SharesWeighted
Average
Remaining
Contractual
Life (in
Years)
$0.06 – 0.40
1,830 5.211,830 5.21
1.55 – 1.75
959 6.43959 6.43
2.43 – 3.11
3,037 7.502,921 7.42
5.01 – 6.82
6,190 9.21977 9.17
8.13 – 9.41
1,569 8.131,301 8.04
12.21 – 15.17
865 8.19401 8.03
  14,450 8,389 
Share-based Payment Arrangement, Restricted Stock Unit, Activity
RSU activity (excluding the performance RSUs outlined below) is as follows (in thousands, except for weighted average grant date fair value):

SharesWeighted Average
Grant Date
Fair Value
Unvested at December 31, 202211,601 $6.40 
Granted10,198 9.64 
Vested(5,202)7.54 
Forfeited and expired(2,114)7.40 
Unvested at December 31, 202314,483 $8.08 
Share-based Payment Arrangement, Expensed and Capitalized, Amount
The following table summarizes stock-based compensation expense for employees and nonemployees, by category, on the consolidated statements of operations and comprehensive loss for the years ended December 31, 2023, 2022, and 2021 (in thousands):

Year Ended December 31,
202320222021
Marketing$5,477 $4,648 $9,664 
Operations and support6,815 2,684 2,735 
Technology and development7,126 4,327 4,481 
General and administrative46,662 31,158 50,331 
Total stock-based compensation expense$66,080 $42,817 $67,211